BOSTON SCIENTIFIC CORP · Surgical & Medical Instruments & Apparatus

BSX

Low riskNext report: Due any day

View price ↗

The short version

A profitable company with steady sales.

Going well

Profitable
Sales up 20% last year
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions cut 0.6% from their holdings in the quarter ending June 2026 (706 bought, 933 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$45.60-0.1% that day

Company value: $66.1B; Share price times all shares
Price vs profit (P/E): 18.5x; You pay about $18 for each $1 of yearly profit
Price vs sales: 3.1x; Company value is 3.1 times a year of sales
Cash vs value: 1%; Cash as a share of company value
Debt vs value: 17%; Debt as a share of company value

From BSX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$5.4B+7.5% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $21.0B, up 14% from the 12 months before. Over 5 years, sales grew about 15% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of BSX. Starting points are the company's recent numbers.

Sales growth+14% a yearRecently: +14% a yearProfit margin17%Last 12 months: 17.5%P/E at the end18xToday: 18.5x. Many steady companies trade at 12x to 25xShare count change+1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$40.4B

Profit in 5 years$6.9B

Price these guesses point to$81.22+78% vs $45.60 todayAbout +12% a year, before dividends

What today's price needs: with a 17% margin and a 18x P/E, sales would have to grow about 1.6% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

4/7Mixed

MissReturn on equity 15%+Earns a lot on the money owners have in the business.12.6%
PassDebt under half of equityNot relying on borrowed money.0.46x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.14.4%
MissProfitable every yearSteady profits, not one good year.9 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$3.7B
MissShare count not growingNot diluting owners. Falling means buybacks.+3.8% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.69.0%

Revenue: $20.1B; +19.9% vs prior year
5-year growth: +15.2%/yr; revenue, per year
Total debt: $11.1B; 0.46x equity
Current ratio: 1.62x; short-term assets / bills due

From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.